CD36-mediated uptake of surfactant lipids by human macrophages promotes intracellular growth of mycobacterium tuberculosis

Journal of Immunology

Volumn 197, Issue 12, 2016, Pages 4727-4735

  Dodd, Claire E ^a   Pyle, Charlie J ^a   Glowinski, Rebecca ^a   Rajaram, Murugesan V S ^a   Schlesinger, Larry S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUNG SURFACTANT; SURFACTANT PROTEIN A; TUMOR NECROSIS FACTOR; SMALL INTERFERING RNA;

ARTICLE; BACTERIAL GROWTH; CARBON SOURCE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; LIPID TRANSPORT; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE CULTURE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; UPREGULATION; CELL CULTURE; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INNATE IMMUNITY; LIPID METABOLISM; LUNG; LUNG TUBERCULOSIS; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHAGOCYTOSIS;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANTIGENS, CD36; CELLS, CULTURED; HUMANS; IMMUNITY, INNATE; INTRACELLULAR SPACE; LIPID METABOLISM; LUNG; MACROPHAGES, ALVEOLAR; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANTS; RNA, SMALL INTERFERING; TUBERCULOSIS, PULMONARY;

EID: 85002045605     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600856     Document Type: Article

References (74)

1. WHO. 2014. Global Tuberculosis Report 2014. WHO, Geneva.
2. Suter, E. 1952. The multiplication of tubercle bacilli within normal phagocytes in tissue culture. J. Exp. Med. 96: 137-150.
3. Rajaram, M. V. S., B. Ni, C. E. Dodd, and L. S. Schlesinger. 2014. Macrophage immunoregulatory pathways in tuberculosis. Semin. Immunol. 26: 471-485.
4. Hussell, T., and T. J. Bell. 2014. Alveolar macrophages: plasticity in a tissuespecific context. Nat. Rev. Immunol. 14: 81-93.
5. Ferguson, J. S., and L. S. Schlesinger. 2000. Pulmonary surfactant in innate immunity and the pathogenesis of tuberculosis. Tuber. Lung Dis. 80: 173-184.
6. Guirado, E., U. Mbawuike, T. L. Keiser, J. Arcos, A. K. Azad, S.-H. Wang, and L. S. Schlesinger. 2015. Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model. MBio 6: e02537-e14.
7. Crowther, J. E., V. K. Kutala, P. Kuppusamy, J. S. Ferguson, A. A. Beharka, J. L. Zweier, F. X. McCormack, and L. S. Schlesinger. 2004. Pulmonary surfactant protein A inhibits macrophage reactive oxygen intermediate production in response to stimuli by reducing NADPH oxidase activity. J. Immunol. 172: 6866-6874.
8. Gaynor, C. D., F. X. McCormack, D. R. Voelker, S. E. McGowan, and L. S. Schlesinger. 1995. Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J. Immunol. 155: 5343-5351.
9. Beharka, A. A., C. D. Gaynor, B. K. Kang, D. R. Voelker, F. X. McCormack, and L. S. Schlesinger. 2002. Pulmonary surfactant protein A upregulates activity of the mannose receptor, a pattern recognition receptor expressed on human macrophages. J. Immunol. 169: 3565-3573.
10. Nguyen, H. A., M. V. S. Rajaram, D. A. Meyer, and L. S. Schlesinger. 2012. Pulmonary surfactant protein A and surfactant lipids regulate IRAK-M, a negative regulator of TLR-mediated inflammation in human macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 303: L608-L616.
11. Henning, L. N., A. K. Azad, K. V. Parsa, J. E. Crowther, S. Tridandapani, and L. S. Schlesinger. 2008. Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages. J. Immunol. 180: 7847-7858.
12. Harrod, K. S., B. C. Trapnell, K. Otake, T. R. Korfhagen, and J. A. Whitsett. 1999. SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. Am. J. Physiol. 277: L580-L588.
13. Clark, H., N. Palaniyar, P. Strong, J. Edmondson, S. Hawgood, and K. B. M. Reid. 2002. Surfactant protein D reduces alveolar macrophage apoptosis in vivo. J. Immunol. 169: 2892-2899.
14. Arcos, J., S. J. Sasindran, N. Fujiwara, J. Turner, L. S. Schlesinger, and J. B. Torrelles. 2011. Human lung hydrolases delineate Mycobacterium tuberculosis-macrophage interactions and the capacity to control infection. J. Immunol. 187: 372-381.
15. Rajaram, M. V., M. N. Brooks, J. D. Morris, J. B. Torrelles, A. K. Azad, and L. S. Schlesinger. 2010. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. J. Immunol. 185: 929-942.
16. Wilsher, M. L., D. J. Parker, and P. L. Haslam. 1990. Immunosuppression by pulmonary surfactant: mechanisms of action. Thorax 45: 3-8.
17. Guth, A. M., W. J. Janssen, C. M. Bosio, E. C. Crouch, P. M. Henson, and S. W. Dow. 2009. Lung environment determines unique phenotype of alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 296: L936-L-946.
18. Yamashita, C. M., R. A. W. Veldhuizen, and S. E. Gill. 2013. Alveolar macrophages and pulmonary surfactant: more than just friendly neighbors. OA Biol. 1:6.
19. Schlesinger, L. S., ed. 1997. Mononuclear phagocytes in tuberculosis. In Lung Macrophages and Dendritic Cells in Health and Disease for the series Lung Biology in Health and Disease, Vol. 102. Marcel Dekker, New York, p. 437-480.
20. Carlson, T. K., M. N. Brooks, M. V. S. Rajaram, L. N. Henning, D. A. Meyer, and L. S. Schlesinger. 2010. Pulmonary innate immunity: soluble and cellular host defenses of the lung. In Regulation of Innate Immune Function. M. H. Tridandapani, ed. Transworld Research Signpost, STM Books, Kerala, India, p. 167-211.
21. Goerke, J. 1998. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1408: 79-89.
22. Weaver, T. E., and J. J. Conkright. 2001. Function of surfactant proteins B and C. Annu. Rev. Physiol. 63: 555-578.
23. Wright, J. R., and D. C. Youmans. 1995. Degradation of surfactant lipids and surfactant protein A by alveolar macrophages in vitro. Am. J. Physiol. 268: L772-L780.
24. Eckert, H., M. Lux, and B. Lachmann. 1983. The role of alveolar macrophages in surfactant turnover. An experimental study with metabolite VIII of bromhexine (Ambroxol). Lung 161: 213-218.
25. Baker, A. D., A. Malur, B. P. Barna, S. Ghosh, M. S. Kavuru, A. G. Malur, and M. J. Thomassen. 2010. Targeted PPARgamma deficiency in alveolar macrophages disrupts surfactant catabolism. J. Lipid Res. 51: 1325-1331.
26. Forbes, A., M. Pickell, M. Foroughian, L. J. Yao, J. Lewis, and R. Veldhuizen. 2007. Alveolar macrophage depletion is associated with increased surfactant pool sizes in adult rats. J. Appl. Physiol. 103: 637-645.
27. Poelma, D. L., M. R. Ju, S. C. Bakker, L. J. Zimmermann, B. F. Lachmann, and J. F. van Iwaarden. 2004. A common pathway for the uptake of surfactant lipids by alveolar cells. Am. J. Respir. Cell Mol. Biol. 30: 751-758.
28. Guthmann, F., R. Haupt, A. C. Looman, F. Spener, and B. Rüstow. 1999. Fatty acid translocase/CD36 mediates the uptake of palmitate by type II pneumocytes. Am. J. Physiol. 277: L191-L196.
29. Koonen, D. P. Y., J. F. C. Glatz, A. Bonen, and J. J. F. P. Luiken. 2005. Longchain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta 1736: 163-180.
30. Glatz, J. F., J. J. Luiken, and A. Bonen. 2010. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol. Rev. 90: 367-417.
31. Hoebe, K., P. Georgel, S. Rutschmann, X. Du, S. Mudd, K. Crozat, S. Sovath, L. Shamel, T. Hartung, U. Zähringer, and B. Beutler. 2005. CD36 is a sensor of diacylglycerides. Nature 433: 523-527.
32. Stewart, C. R., L. M. Stuart, K. Wilkinson, J. M. van Gils, J. Deng, A. Halle, K. J. Rayner, L. Boyer, R. Zhong, W. A. Frazier, et al. 2010. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11: 155-161.
33. Erdman, L. K., G. Cosio, A. J. Helmers, D. C. Gowda, S. Grinstein, and K. C. Kain. 2009. CD36 and TLR interactions in inflammation and phagocytosis: implications for malaria. J. Immunol. 183: 6452-6459.
34. Won, W.-J., M. F. Bachman, and J. F. Kearney. 2008. CD36 is differentially expressed on B cell subsets and in response to antigen. J. Immunol. 180: 230-237.
35. Huh, H. Y., S. F. Pearce, L. M. Yesner, J. L. Schindler, and R. L. Silverstein. 1996. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 87: 2020-2028.
36. Asada, K., S. Sasaki, T. Suda, K. Chida, and H. Nakamura. 2004. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am. J. Respir. Crit. Care Med. 169: 195-200.
37. Cai, Y., C. Sugimoto, M. Arainga, X. Alvarez, E. S. Didier, and M. J. Kuroda. 2014. In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. J. Immunol. 192: 2821-2829.
38. Palanisamy, G. S., N. M. Kirk, D. F. Ackart, A. Obregón-Henao, C. A. Shanley, I. M. Orme, and R. J. Basaraba. 2012. Uptake and accumulation of oxidized lowdensity lipoprotein during Mycobacterium tuberculosis infection in guinea pigs. PLoS One 7: e34148.
39. Hawkes, M., X. Li, M. Crockett, A. Diassiti, C. Finney, G. Min-Oo, W. C. Liles, J. Liu, and K. C. Kain. 2010. CD36 deficiency attenuates experimental mycobacterial infection. BMC Infect. Dis. 10:299.
40. Court, N., V. Vasseur, R. Vacher, C. Frémond, Y. Shebzukhov, V. V. Yeremeev, I. Maillet, S. A. Nedospasov, S. Gordon, P. G. Fallon, et al. 2010. Partial redundancy of the pattern recognition receptors, scavenger receptors, and C-type lectins for the long-term control of Mycobacterium tuberculosis infection. J. Immunol. 184: 7057-7070.
41. Sharif, O., U. Matt, S. Saluzzo, K. Lakovits, I. Haslinger, T. Furtner, B. Doninger, and S. Knapp. 2013. The scavenger receptor CD36 downmodulates the early inflammatory response while enhancing bacterial phagocytosis during pneumococcal pneumonia. J. Immunol. 190: 5640-5648.
42. Stuart, L. M., J. Deng, J. M. Silver, K. Takahashi, A. A. Tseng, E. J. Hennessy, R. A. B. Ezekowitz, and K. J. Moore. 2005. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J. Cell Biol. 170: 477-485.
43. Blanchet, C., G. Jouvion, C. Fitting, J. Cavaillon, and M. Adib-Conquy. 2014. Protective or deleterious role of scavenger receptors SR-A and CD36 on host resistance to Staphylococcus aureus depends on site of infection. PLoS One 1: e87927.
44. Oquendo, P., E. Hundt, J. Lawler, and B. Seed. 1989. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell 58: 95-101.
45. Lee, W., B. C. VanderVen, R. J. Fahey, and D. G. Russell. 2013. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J. Biol. Chem. 288: 6788-6800.
46. Pandey, A. K., and C. M. Sassetti. 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc. Natl. Acad. Sci. USA 105: 4376-4380.
47. Daniel, J., H. Maamar, C. Deb, T. Sirakova, and P. Kolattukudy. 2011. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog. 7: e1002093.
48. Rodríguez, J. G., A. C. Hernández, C. Helguera-Repetto, D. Aguilar Ayala, R. Guadarrama-Medina, J. M. Anzóla, J. R. Bustos, M. M. Zambrano, J. González-Y-Merchand, M. J. García, and P. Del Portillo. 2014. Global adaptation to a lipid environment triggers the dormancy-related phenotype of Mycobacterium tuberculosis. MBio 5: e01125-e14.
49. Peyron, P., J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. Daffé, J. F. Emile, B. Marchou, P. J. Cardona, et al. 2008. Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog. 4: e1000204.
50. Kim, M. J., H. C. Wainwright, M. Locketz, L. G. Bekker, G. B. Walther, C. Dittrich, A. Visser, W. Wang, F.-F. Hsu, U. Wiehart, et al. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2: 258-274.
51. Hunter, R. L., C. Jagannath, and J. K. Actor. 2007. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb.) 87: 267-278.
52. Nichols, B. A. 1976. Normal rabbit alveolar macrophages. I. The phagocytosis of tubular myelin. J. Exp. Med. 144: 906-919.
53. Nichols, B. A. 1976. Normal rabbit alveolar macrophages. II. Their primary and secondary lysosomes as revealed by electron microscopy and cytochemistry. J. Exp. Med. 144: 920-932.
54. Kuroki, Y., R. J. Mason, and D. R. Voelker. 1988. Pulmonary surfactant apoprotein A structure and modulation of surfactant secretion by rat alveolar type II cells. J. Biol. Chem. 263: 3388-3394.
55. Schlesinger, L. S. 1993. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150: 2920-2930.
56. Rajaram, M. V. S. B., B. Ni, J. D. Morris, M. N. Brooks, T. K. Carlson, B. Bakthavachalu, D. R. Schoenberg, J. B. Torrelles, and L. S. Schlesinger. 2011. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc. Natl. Acad. Sci. USA 108: 17408-17413.
57. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
58. Salunke, S. B., A. K. Azad, N. P. Kapuriya, J. M. Balada-Llasat, P. Pancholi, L. S. Schlesinger, and C. S. Chen. 2015. Design and synthesis of novel antituberculosis agents from the celecoxib pharmacophore. Bioorg. Med. Chem. 23: 1935-1943.
59. Luiken, J. J., D. J. Dyck, X. X. Han, N. N. Tandon, Y. Arumugam, J. F. Glatz, and A. Bonen. 2002. Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am. J. Physiol. Endocrinol. Metab. 282: E491-E495.
60. Chabowski, A., J. Górski, J. Calles-Escandon, N. N. Tandon, and A. Bonen. 2006. Hypoxia-induced fatty acid transporter translocation increases fatty acid transport and contributes to lipid accumulation in the heart. FEBS Lett. 580: 3617-3623.
61. Gough, P. J., D. R. Greaves, H. Suzuki, T. Hakkinen, M. O. Haltunen, M. P. Talrunen, S. Y. Herttuala, T. Kodama, and S. Gordon. 1999. Analysis of scavenger receptor a (SR-A) expression in human aortic atherosclerotic lesions. Arterioscl. Throm. Vasc. Biol. 19: 461-471.
62. Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 76: 333-337.
63. Moore, K. J., E. D. Rosen, M. L. Fitzgerald, F. Randow, L. P. Andersson, D. Altshuler, D. S. Milstone, R. M. Mortensen, B. M. Spiegelman, and M. W. Freeman. 2001. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7: 41-47.
64. Barnes, P. F., S.-J. Fong, P. J. Brennan, P. E. Twomey, A. Mazumder, and R. L. Modlin. 1990. Local production of tumor necrosis factor and IFN-g in tuberculous pleuritis. J. Immunol. 145: 149-154.
65. Nagabhushanam, V., A. Solache, L.-M. Ting, C. J. Escaron, J. Y. Zhang, and J. D. Ernst. 2003. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis- induced IL-6 inhibits macrophage responses to IFN-g. J. Immunol. 171: 4750-4757.
66. Allen, J. N., S. A. Moore, A. L. Pope-Harman, C. B. Marsh, and M. D. Wewers. 1995. Immunosuppressive properties of surfactant and plasma on alveolar macrophages. J. Lab. Clin. Med. 125: 356-369.
67. Antal, J. M., L. T. Divis, S. C. Erzurum, H. P. Wiedemann, and M. J. Thomassen. 1996. Surfactant suppresses NF-kappa B activation in human monocytic cells. Am. J. Respir. Cell Mol. Biol. 14: 374-379.
68. Thomassen, M. J., J. M. Antal, B. P. Barna, L. T. Divis, D. P. Meeker, and H. P. Wiedemann. 1996. Surfactant downregulates synthesis of DNA and inflammatory mediators in normal human lung fibroblasts. Am. J. Physiol. 270: L159-L163.
69. Harris, J., J. C. Hope, and J. Keane. 2008. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J. Infect. Dis. 198: 1842-1850.
70. Underhill, D. M., A. Ozinsky, K. D. Smith, and A. Aderem. 1999. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc. Natl. Acad. Sci. USA 96: 14459-14463.
71. Nesbitt, N. M., X. Yang, P. Fontán, I. Kolesnikova, I. Smith, N. S. Sampson, and E. Dubnau. 2010. A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect. Immun. 78: 275-282.
72. VanderVen, B. C., R. J. Fahey, W. Lee, Y. Liu, R. B. Abramovitch, C. Memmott, A. M. Crowe, L. D. Eltis, E. Perola, D. D. Deininger, et al. 2015. Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment. PLoS Pathog. 11: e1004679.
73. Griffin, J. E., A. K. Pandey, S. A. Gilmore, V. Mizrahi, J. D. McKinney, C. R. Bertozzi, and C. M. Sassetti. 2012. Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem. Biol. 19: 218-227.
74. Yang, X., J. Gao, I. Smith, E. Dubnau, and N. S. Sampson. 2011. Cholesterol is not an essential source of nutrition for Mycobacterium tuberculosis during infection. J. Bacteriol. 193: 1473-1476.